Page 258 - Read Online

Page 8 of 9 Bose et al. Hepatoma Res 2019;5:24 I http://dx.doi.org/10.20517/2394-5079.2019.10

DECLARATIONS
Authors’ contributions
Literature survey; Data analysis and comparison of published data; Draft of the manuscript: Bose PP
Draft of the Manuscript and comparison of published data: Chatterjee U

Availability of data and materials
Not applicable.

Financial support and sponsorship
Not applicable.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCE
1. Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control
2017;24:1073274817729245.
2. Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring
cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711-42.
3. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, et al. Risk of hepatocellular cancer in patients with non-alcoholic
fatty liver disease. Gastroenterology 2018;155:1828-37.e2.
4. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al, Alpha-fetoprotein, des-γ carboxyprothrombin, and lectin-bound alpha-
fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.
5. Ghanaati H, Alavian SM, Jafarian A, Ebrahimi Daryani N, Nassiri-Toosi M. Imaging and imaging-guided interventions in the diagnosis
and management of hepatocellular carcinoma (HCC)-review of evidence. Iran J Radiol 2012;9:167-77.
6. Haug AR.. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma Imaging of primary liver
tumors with positron-emission tomography. Q J Nucl Med Mol Imaging 2017;61:292-300.
7. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, et al. Asian pacific association for the study of the liver consensus recommendations
on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.
8. Navin PJ, Venkatesh SK. Hepatocellular carcinoma: state of the art imaging and recent advances. J Clin Transl Hepatol 2019;7:72-85.
9. Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with
histologic differentiation. Radiology 2007;244:898-906.
10. Wu B, Zhang Y, Tan H, Shi H. Value of F-FDG PET/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular
18
carcinoma. Abdom Radiol (NY) 2019; doi: 10.1007/s00261-019-01997-2.
11. Park MS, Kim S, Patel J, Hajdu CH, Do RK, et al. Hepatocellular carcinoma: detection with diffusion weighted versus contrast-
enhanced magnetic resonance imaging in pretransplant patients. Hepatology 2012;56:140-8.
12. Ishizawa T, Masuda K, Urano Y, Kawaguchi Y, Satou S, et al. Mechanistic background and clinical applications of indocyanine green
fluorescence imaging of hepatocellular carcinoma. Ann Surg Oncol 2014;21:440-8.
13. Hester CA, Rich NE, Singal AG, Yopp AC. Comparative analysis of nonalcoholic steatohepatitis versus viral hepatitis and alcohol-
related liver disease-related hepatocellular carcinoma. J Natl Compr Canc Netw 2019;17:322-9.
14. Li D, Mallory T, Satomura S. AFP L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001;313:15-9.
15. Liebman HA, Furie BC, Tong M, Blanchard RA, Lo KJ, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary
hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.
16. Wang B, Zhu J, Ma X, Wang H, Qiu S, et al. Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular
carcinoma. Clin Chim Acta 2019;495:191-7.